| TA164 |
Hyperuricaemia - febuxostat (TA164) |
|
-
-
Febuxostat for the management of hyperuricaemia in people with gout
Febuxostat is recommended as a possible treatment for chronic hyperuricaemia in people with gout only if:
- they can't take the medicine allopurinol for medical reasons or
- the side effects of allopurinol are so bad that the person either has to stop taking it or can't be given the most effective dose.
People who were already taking febuxostat when the guidance was issued should be able to carry on taking it until they and their healthcare professional(s) decide that it is the right time to stop treatment.
-
Other information
How this guidance was produced
Background information
This page was last updated: 24 November 2011
-
Guidance formats
-
Implementation tools and resources
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
